AUTHORS
Jason Chen, MD, Jingru Ha2, Ala Almanaseer, MD3, Ani Orchanian-Cheff4, Stephen Betschel5, Lani Lieberman, MD, FRCPC6, Heather Vandermeulen, MD7, Erika Lee, MD8
AFFILIATIONS
1 McMaster University, Hamilton, Ontario, Canada
2 University of Calgary, Calgary, Alberta, Canada
3 University of British Columbia, Vancouver, British Columbia, Canada
4 University of Toronto, Toronto, Ontario, Canada
5 University of Toronto, Toronto, Ontario, Canada
6 University of Toronto, Toronto, Ontario, Canada
7 University of Toronto, Toronto, Ontario, Canada
8 University of Toronto, Toronto, Ontario, Canada
ABSTRACT
Introduction: Secondary hypogammaglobulinemia (SHG) is defined as serum immunoglobulin G (IgG) level <7 g/dL not otherwise caused by underlying inborn error of immunity (IEI). Common etiologies of SHG include hematologic malignancies, immunomodulatory medications, hematopoietic and solid organ transplantation, autoimmune diseases, and protein-losing conditions including nephrotic syndrome and protein-losing enteropathies. Patients with hypogammaglobulinemia are at increased susceptibility to infections, particularly bacterial pneumonia and sepsis. SHG is managed first-line with immunoglobulin replacement, most commonly intravenous immunoglobulin (IVIG). Subcutaneous immunoglobulin (SCIG) is a similar formulation with comparable outcomes and efficacy in primary immunodeficiency, but with limited data in a SHG population. This study investigated the efficacy of SCIG in comparison to IVIG in the management of SHG.
Methods: A systematic search was conducted in Ovid MEDLINE, Ovid Embase, Cochrane Database of Systematic Reviews (Ovid), and Cochrane Central Register of Controlled Trials (Ovid), from inception until October 2024. Inclusion criteria consisted of all patients with SHG, defined as serum IgG <7 g/L not caused by inborn error of immunity, treated with SCIG compared to IVIG or no treatment. All publication types were included. Outcomes extracted included diagnoses leading to SHG, infection rates, and IgG levels. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under CRD42025646068.
Results: A total of 38 studies were eligible for data extraction, consisting of 1173 patients with SHG. Hematologic and oncologic diagnoses were the most common etiologies of SHG requiring SCIG, consisting primarily of chronic lymphocytic leukemia (n=428), lymphoma (n=160), and multiple myeloma (n=137). Other common etiologies included post-hematopoietic stem cell transplantation (n=96), anti-CD20 therapy (n=38), and solid organ transplantation (n=18). Infection rates ranged from 0.30–15.14 infections/patient-year in the no treatment group, 1.00–3.14 infections/patient-year in the IVIG group, and 0–3.54 infections/patient-year in the SCIG group. Serum IgG levels ranged from 0.70–5.77 g/L in the no treatment group, 3.45–7.00 g/L in the IVIG group, and 6.02–10.68 g/L in the SCIG group. Meta-analysis of 3 studies compared infection rates showed similar rates in the SCIG and IVIG groups, with a difference of 0.42 infections/patient-year fewer infections in the SCIG group relative to the IVIG group (95% confidence interval -1.31 to 0.47). Meta-analysis of 9 studies comparing IgG levels showed higher IgG in the SCIG group by 1.26 g/L (95% confidence interval 0.50 to 2.03). Adverse event data was gathered on 278 patients using SCIG, and 190 patients using IVIG. The proportion of adverse events was significant higher in IVIG group compared to SCIG (38.9% compared to 12.6% respectively, p<0.001). The most common adverse events in SCIG patients were injection site pain/pruritus/swelling (2.5%), fevers/chills (2.2%), and bruising (2.2%). The most common adverse events in IVIG patients were headaches (17.4%), fever/chills (10.0%), and diffuse dermatologic reactions (2.6%).
Conclusions: SHG etiologies requiring SCIG in the literature are predominantly hematologic malignancies. The meta-analysis showed no significant difference in infection rates between SCIG and IVIG, and higher IgG levels and lower rates of adverse events associated with SCIG compared to IVIG. These findings suggest that SCIG has comparable efficacy when compared to IVIG in SHG and should be considered as an alternative management option.
DISCLOSURES
Jason Chen, MD: No relevant conflicts of interest to declare.